Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary tenecteplase after primary PCI in STEMI with high IMR
ACTRN12618000778280Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute ST-segment elevation myocardial infarction (STEMI) comparing Tenecteplase with Placebo (2 arms). Primary endpoints: Cardiovascular mortality and Re-hospitalisation for heart failure. Started Oct 2018; status: completed.
02
Drugs
tenecteplase
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ACTRN12618000778280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000778280.